Independent Research
IBRX Analysis
8 pieces of research on ImmunityBio, Inc.. We find the signal management buried in the earnings call.
ImmunityBio Directors Sold $3.9M Before Earnings Miss
Three ImmunityBio directors completed $3.92 million in open-market share sales between June 4 and July 2, before an August 4 earnings report that disclosed a 17…
Read analysis →ImmunityBio Insiders Banked $3.92M Above Current Price
Three ImmunityBio directors sold $3.92M in shares at $7.18-$9.50 weeks before the company reported its worst EPS miss in four quarters, a -175% shortfall agains…
Read analysis →ImmunityBio Directors Sold $3.92M Before Earnings Miss
Three ImmunityBio board members sold $3.92 million in shares at prices between $7.18 and $9.50 between June 4 and July 2, 2026, weeks before the company reporte…
Read analysis →ImmunityBio Lands BCG Deal as Anktiva FDA Ruling Nears
ImmunityBio is acquiring U.S. rights to the Tokyo strain of BCG to target a decade-long bladder cancer shortage, while a pivotal FDA decision on its Anktiva imm…
Read analysis →ImmunityBio Grabs BCG Rights Ahead of Make-or-Break FDA Ruling
ImmunityBio is acquiring U.S. rights to Tokyo strain BCG while bracing for an imminent Anktiva FDA ruling, a dual catalyst that creates a binary risk event for …
Read analysis →ImmunityBio Got Promising Trial Data and an FDA Warning Letter in the Same Month
ImmunityBio confirmed its pivotal BCG-naive bladder cancer trial has adequate statistical power for a 2026 supplemental filing, but an FDA warning letter over m…
Read analysis →